KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2016 - 2026)

Bio-Rad Laboratories has reported Liabilities and Shareholders Equity over the past 18 years, most recently at $9.8 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 3077.54% to $9.8 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $40.3 billion through Mar 2026, up 316.42% year-over-year, with the annual reading at $10.6 billion for FY2025, 12.95% up from the prior year.
  • Liabilities and Shareholders Equity was $9.8 billion for Q1 2026 at Bio-Rad Laboratories, down from $10.6 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $14.4 billion in Q1 2022 and troughed at $300000.0 in Q4 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $10.2 billion (2025), against an average of $8.5 billion.
  • Year-over-year, Liabilities and Shareholders Equity plummeted 99.71% in 2022 and then surged 3121266.67% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $600000.0 in 2022, then crashed by 50.0% to $300000.0 in 2023, then surged by 3121266.67% to $9.4 billion in 2024, then increased by 12.95% to $10.6 billion in 2025, then decreased by 7.44% to $9.8 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Liabilities and Shareholders Equity are $9.8 billion (Q1 2026), $10.6 billion (Q4 2025), and $9.7 billion (Q3 2025).